These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 34253646

  • 1. Preclinical Evaluation of the Effects of Trazpiroben (TAK-906), a Novel, Potent Dopamine D2/D3 Receptor Antagonist for the Management of Gastroparesis.
    Whiting RL, Choppin A, Luehr G, Jasper JR.
    J Pharmacol Exp Ther; 2021 Oct; 379(1):85-95. PubMed ID: 34253646
    [Abstract] [Full Text] [Related]

  • 2. Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D2 /D3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants.
    Whiting RL, Darpo B, Chen C, Fletcher M, Combs D, Xue H, Stoltz RR.
    Clin Pharmacol Drug Dev; 2021 Aug; 10(8):927-939. PubMed ID: 33462988
    [Abstract] [Full Text] [Related]

  • 3. Randomised clinical trial: safety, pharmacokinetics and pharmacodynamics of trazpiroben (TAK-906), a dopamine D2 /D3 receptor antagonist, in patients with gastroparesis.
    Kuo B, Scimia C, Dukes G, Zhang W, Gupta S, Chen C, Chuang E, Camilleri M.
    Aliment Pharmacol Ther; 2021 Aug; 54(3):267-280. PubMed ID: 34148244
    [Abstract] [Full Text] [Related]

  • 4. Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15.
    Kiss B, Laszlovszky I, Horváth A, Némethy Z, Schmidt E, Bugovics G, Fazekas K, Gyertyán I, Agai-Csongor E, Domány G, Szombathelyi Z.
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Nov; 378(5):515-28. PubMed ID: 18551280
    [Abstract] [Full Text] [Related]

  • 5. Non-Clinical Safety Pharmacology Evaluations of Trazpiroben (TAK-906), a Novel Dopamine D2/D3 Selective Receptor Antagonist for the Management of Gastroparesis.
    Kreckler L, Osinski M, Williams S, Whiting R.
    J Exp Pharmacol; 2022 Nov; 14():43-57. PubMed ID: 35173492
    [Abstract] [Full Text] [Related]

  • 6. In vitro pharmacological profile of YM-43611, a novel D2-like receptor antagonist with high affinity and selectivity for dopamine D3 and D4 receptors.
    Hidaka K, Tada S, Matsumoto M, Ohmori J, Tasaki Y, Nomura T, Usuda S, Yamaguchi T.
    Br J Pharmacol; 1996 Apr; 117(8):1625-32. PubMed ID: 8732269
    [Abstract] [Full Text] [Related]

  • 7. The broad-spectrum anti-emetic activity of AS-8112, a novel dopamine D2, D3 and 5-HT3 receptors antagonist.
    Yoshikawa T, Yoshida N, Oka M.
    Br J Pharmacol; 2001 May; 133(2):253-60. PubMed ID: 11350861
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of the Pharmacokinetics of Trazpiroben (TAK-906), a Peripherally Selective D2/D3 Dopamine Receptor Antagonist, in the Presence and Absence of Itraconazole, a Potent CYP 3A4 Inhibitor.
    Chen C, Zhang W, Bari M, Almansa C, Baratta M, Rosario M.
    Clin Pharmacol; 2021 May; 13():145-155. PubMed ID: 34285598
    [Abstract] [Full Text] [Related]

  • 9. Dopamine D3/D2 Receptor Antagonist PF-4363467 Attenuates Opioid Drug-Seeking Behavior without Concomitant D2 Side Effects.
    Wager TT, Chappie T, Horton D, Chandrasekaran RY, Samas B, Dunn-Sims ER, Hsu C, Nawreen N, Vanase-Frawley MA, O'Connor RE, Schmidt CJ, Dlugolenski K, Stratman NC, Majchrzak MJ, Kormos BL, Nguyen DP, Sawant-Basak A, Mead AN.
    ACS Chem Neurosci; 2017 Jan 18; 8(1):165-177. PubMed ID: 27715007
    [Abstract] [Full Text] [Related]

  • 10. Evaluating the Safety, Tolerability, and Disposition of Trazpiroben, a D2 /D3 Receptor Antagonist: Phase I Single- and Multiple-Ascending Dose Studies in Healthy Japanese Participants.
    Yamaguchi T, Kudou K, Okamoto H, Chen C, Whiting R, Sekino H.
    Clin Pharmacol Drug Dev; 2022 Jun 18; 11(6):695-706. PubMed ID: 34967147
    [Abstract] [Full Text] [Related]

  • 11. Glutamate agonists for treating schizophrenia have affinity for dopamine D2High and D3 receptors.
    Seeman P, Guan HC.
    Synapse; 2009 Aug 18; 63(8):705-9. PubMed ID: 19391149
    [Abstract] [Full Text] [Related]

  • 12. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy.
    Millan MJ, Peglion JL, Vian J, Rivet JM, Brocco M, Gobert A, Newman-Tancredi A, Dacquet C, Bervoets K, Girardon S.
    J Pharmacol Exp Ther; 1995 Nov 18; 275(2):885-98. PubMed ID: 7473180
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of 50-kHz ultrasonic vocalizations by dopamine receptor subtype-selective agonists and antagonists in adult rats.
    Scardochio T, Clarke PB.
    Psychopharmacology (Berl); 2013 Apr 18; 226(3):589-600. PubMed ID: 23192317
    [Abstract] [Full Text] [Related]

  • 14. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors.
    Millan MJ, Mannoury la Cour C, Novi F, Maggio R, Audinot V, Newman-Tancredi A, Cussac D, Pasteau V, Boutin JA, Dubuffet T, Lavielle G.
    J Pharmacol Exp Ther; 2008 Feb 18; 324(2):587-99. PubMed ID: 18024789
    [Abstract] [Full Text] [Related]

  • 15. Blonanserin extensively occupies rat dopamine D3 receptors at antipsychotic dose range.
    Baba S, Enomoto T, Horisawa T, Hashimoto T, Ono M.
    J Pharmacol Sci; 2015 Mar 18; 127(3):326-31. PubMed ID: 25837930
    [Abstract] [Full Text] [Related]

  • 16. Pharmacological actions of a novel and selective dopamine D3 receptor antagonist, KCH-1110.
    Park WK, Jeong D, Yun CW, Lee S, Cho H, Kim GD, Koh HY, Pae AN, Cho YS, Choi KI, Jung JY, Jung SH, Kong JY.
    Pharmacol Res; 2003 Dec 18; 48(6):615-22. PubMed ID: 14527827
    [Abstract] [Full Text] [Related]

  • 17. Role of dopamine D2-like receptors in cocaine self-administration: studies with D2 receptor mutant mice and novel D2 receptor antagonists.
    Caine SB, Negus SS, Mello NK, Patel S, Bristow L, Kulagowski J, Vallone D, Saiardi A, Borrelli E.
    J Neurosci; 2002 Apr 01; 22(7):2977-88. PubMed ID: 11923462
    [Abstract] [Full Text] [Related]

  • 18. Apomorphine-induced emesis in dogs: differential sensitivity to established and novel dopamine D2/5-HT(1A) antipsychotic compounds.
    Depoortère R, Barret-Grévoz C, Bardin L, Newman-Tancredi A.
    Eur J Pharmacol; 2008 Nov 12; 597(1-3):34-8. PubMed ID: 18773888
    [Abstract] [Full Text] [Related]

  • 19. Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents.
    Sautel F, Griffon N, Sokoloff P, Schwartz JC, Launay C, Simon P, Costentin J, Schoenfelder A, Garrido F, Mann A.
    J Pharmacol Exp Ther; 1995 Dec 12; 275(3):1239-46. PubMed ID: 8531087
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of the drug-drug interaction potential for trazpiroben (TAK-906), a D2/D3 receptor antagonist for gastroparesis, towards cytochrome P450s and transporters.
    Nishihara M, Ramsden D, Balani SK.
    Xenobiotica; 2021 Jun 12; 51(6):668-679. PubMed ID: 33879032
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.